Robert Preissner

Country flagGermany

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Introduction: Even in times of new therapy regimes, the overall survival of patients with head and neck cancer remains low. Since the previous studies showed the beneficial effect of metformin medication on the survival of patients with cancer, our objective was to investigate if—and in which way—metformin medication affects the overall survival of patients with head and neck cancer. Methods: Clinical data pertaining to patients diagnosed with head and neck cancer (International Classification of Diseases 10 codes C00-C14, C31, and C32) were retrospectively retrieved from the TriNetX network (TriNetX, Cambridge, MA, USA). The initial cohort extracted from the network was stratified into two groups: patients on metformin medication (cohort I), and individuals not on metformin medication (cohort II). The matching criteria included age, gender, BMI, type 2 diabetes, and risk factors, such as nicotine and alcohol abuse/dependence. Kaplan–Meier analysis, risk analysis, and the calculation of odds and hazard ratios were conducted. Additionally, the Hemoglobin A1c values were subject to analysis. Results: Following matching, each cohort comprised 20,416 patients. Cohort I exhibited a higher five-year survival rate at 75.3%, in contrast to cohort II, which registered a rate of 69.8%. The odds ratio was 0.79 (95% CI = 0.75–0.83), and the hazard ratio was 0.78 (95% CI = 0.75–0.82). Conclusion: Metformin medication may correlate with improved five-year survival rates in patients with head and neck cancer. Since potentially influencing factors such as comorbidities and the initial tumor stage were not available, the results of our retrospectively conducted study must be interpreted with caution.

Year:

2024

Interaction with chemicals, present in drugs, food, environments, and consumer goods, is an integral part of our everyday life. However, depending on the amount and duration, such interactions can also result in adverse effects. With the increase in computational methods, the in silico methods can offer significant benefits to both regulatory needs and requirements for risk assessments and the pharmaceutical industry to assess the safety profile of a chemical. Here, we present ProTox 3.0, which incorporates molecular similarity and machine-learning models for the prediction of 61 toxicity endpoints such as acute toxicity, organ toxicity, clinical toxicity, molecular-initiating events (MOE), adverse outcomes (Tox21) pathways, several other toxicological endpoints and toxicity off-targets. All the ProTox 3.0 models are validated on independent external sets and have shown strong performance. ProTox envisages itself as a complete, freely available computational platform for in silico toxicity prediction for toxicologists, regulatory agencies, computational chemists, and medicinal chemists. The ProTox 3.0 webserver is free and open to all users, and there is no login requirement and can be accessed via https://tox.charite.de. The web server takes a 2D chemical structure as input and reports the toxicological profile of the compound for each endpoint with a confidence score and overall toxicity radar plot and network plot.

Year:

2024

Background The role of viral agents in the development of head and neck cancers has remained controversial. While markers of viral origin have been isolated from oral cancer tissues, a causative relationship has yet to be shown. The aim of this study was to evaluate the relationship between head and neck cancers and Herpes simplex virus, one of the most common viral infections of the oral orifice. Methods Here, we conducted a retrospective analysis of two age‐ and gender‐matched cohorts extracted from the real‐world database TriNetX on March 10th, 2023, each consisting of 249,272 patients with and without Herpes simplex infections (ICD‐10: B00). The diagnoses C00‐C14 were analyzed, and risk analysis and Kaplan‐Meier survival statics were computed. Results The strongest association was found for lip cancer (ICD‐10: C00) with a hazard ratio [HR (CI 95% low‐high)] of 3.08 (1.77–5.35). A significant association with HR of 1.17 (1.02–1.34) was found for the entire group of head and neck cancers. Confounders like smoking and alcohol dependence were considered using propensity score matching. Conclusion The surprisingly strong correlation with lip, oral cavity, and pharynx neoplasms sheds new light on supposedly harmless herpes simplex infections, suggesting them as a possible new factor for risk stratification.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (14)

Felix Behrens

Charité - Universitätsmedizin Berlin

GERMANY
View details

Susanne Nahles

Charité - Universitätsmedizin Berlin

GERMANY
View details

Carsten Rendenbach

Charité - Universitätsmedizin Berlin

GERMANY
View details

Marina BORRO

Associate Professor - Biochemistry

Sapienza University of Rome

ITALY
View details

Renata Abel

Charité - Universitätsmedizin Berlin

GERMANY
View details

Philip Bourne

University of Virginia

UNITED STATES
View details

Saskia Preissner

-

GERMANY
View details

Paolo Marchetti

Sapienza University of Rome

ITALY
View details

SIMONA PISEGNA

Sapienza University of Rome

ITALY
View details

Robert Szulcek

Assoc. Prof. (W2)

Charité - Universitätsmedizin Berlin

GERMANY
View details

Jonas Wüster

-

GERMANY
View details

Maurizio Pompili

Sapienza University of Rome

ITALY
View details

Silvia MEZI

Aggregate professor

Sapienza University of Rome

ITALY
View details

Antonio Del Casale

Associate Professor

Sapienza University of Rome

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.